{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-137472","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.354835+00:00","generated_at":"2026-06-28T09:27:23.642675+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organon Q3 revenue $1.6B (-1% YoY); adj. EPS $1.67; FY guidance narrowed; dividend $0.28","bullets":["Revenue $1,600M, down 1% as-reported and 3% ex-FX YoY; net income from continuing ops $323M ($1.27 diluted EPS).","Adjusted net income $424M ($1.67 diluted EPS); Adjusted EBITDA $636M (39.8% margin).","Women's Health revenue $381M (-10% as-reported); Biosimilars +41%; Established Brands -6%.","Board declares Q4 dividend $0.28/share, payable Dec 16, 2021, record Nov 22, 2021.","Affirms FY guidance, narrows revenue range to $6.2B-$6.3B and Adj. EBITDA margin to 36.5%-37.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-137472","json":"https://secwatch.observer/filing/0001104659-21-137472.json","markdown":"https://secwatch.observer/filing/0001104659-21-137472.md","text":"https://secwatch.observer/filing/0001104659-21-137472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/0001104659-21-137472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/tm2131080d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:27:23.642675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}